Key facts
- This page summarizes Onaiza Cadoret-Manier's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Jan 2024, 18:07.
Onaiza Cadoret-Manier - 16 Jan 2024 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)
- Reporting relationship
- EVP, Chf GL Pdt Str & Oper Ofc
- Issuer ticker
- IONS
- Reported as of
- 16 Jan 2024
- Net transaction value
- -$280,520
- SEC form
- 4
- Accepted by SEC
- 18 Jan 2024, 18:07:45 UTC
- Prior SEC filing
- 17 Jan 2024
- Next SEC filing
- 23 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- By: Patrick R. O'Neil, attorney-in-fact For: Onaiza Cadoret-Manier
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Onaiza Cadoret-Manier filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 18 Jan 2024.
Change
- Previous filing in this sequence was filed on 17 Jan 2024.
- Current net transaction value: -$280,520.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IONS
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +15,062
- Change %
- +62%
- Price
- $0.000000
- Shares after
- 39,374
- Date
- 16 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
IONS
transaction
Common Stock
Sale
- Transaction value
- $280,520
- Shares
- -5,564
- Change %
- -14%
- Price
- $50.42
- Shares after
- 33,810
- Date
- 17 Jan 2024
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IONS
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -15,062
- Change %
- -18%
- Price
- $0.000000
- Shares after
- 66,997
- Date
- 16 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,062
- Exercise price
- $0.000000
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
Footnote F2
The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
Footnote F3
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.
Footnote F4
Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
Footnote F5
Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.